Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cue Biopharma Inc
(NQ:
CUE
)
0.7000
-0.0291 (-3.99%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cue Biopharma Inc
< Previous
1
2
3
4
Next >
Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 19, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q2 2024
August 15, 2024
CUE stock results show that Cue Biopharma beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Cue Biopharma to Host Business Update Call and Webcast
August 13, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Forecasting The Future: 4 Analyst Projections For Cue Biopharma
April 09, 2024
Via
Benzinga
Cue Biopharma Inc. (NASDAQ: CUE) Leading the Way in Wednesday Trading Based on Percentage Gain
March 13, 2024
Via
Investor Brand Network
Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital Requirements
July 25, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting
June 04, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024
June 03, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Medical Moonshots: 3 Biotech Stocks Set to Skyrocket
May 30, 2024
Though risky, investors who buy biotech stocks watch their portfolios skyrocket when their drugs work as intended.
Via
InvestorPlace
CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q1 2024
May 09, 2024
CUE stock results show that Cue Biopharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 09, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Present at the 20th Annual PEGS Boston Summit
May 08, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference
May 07, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
May 02, 2024
Via
Benzinga
Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights
April 08, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
CUE Stock Earnings: Cue Biopharma Misses EPS, Beats Revenue for Q4 2023
April 02, 2024
CUE stock results show that Cue Biopharma missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Cue Biopharma to Host Business Update Call and Webcast
April 02, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
March 13, 2024
Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24...
Via
Benzinga
Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
February 29, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
January 01, 2024
Via
Benzinga
CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q3 2023
December 14, 2023
CUE stock results show that Cue Biopharma beat analyst estimates for earnings per share and beat on revenue for the third quarter of 2023.
Via
InvestorPlace
Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit
November 22, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
November 09, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November
November 07, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023
November 03, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Host Business Update Call and Webcast
November 02, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
September 27, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®
September 26, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.